The new Xpert MTB/RIF ultra: Improving detection of Mycobacterium tuberculosis and resistance to Rifampin in an assay suitable for point-of-care testing

mBio

Volumn 8, Issue 4, 2017, Pages

  Chakravorty, Soumitesh ^a   Simmons, Ann Marie ^b   Rowneki, Mazhgan ^a   Parmar, Heta ^a   Cao, Yuan ^a   Ryan, Jamie ^b   Banada, Padmapriya P ^a   Deshpande, Srinidhi ^a   Shenai, Shubhada ^a   Gall, Alexander ^c   Glass, Jennifer ^b   Krieswirth, Barry ^d   Schumacher, Samuel G ^e   Nabeta, Pamela ^e   Tukvadze, Nestani ^f   Rodrigues, Camilla ^g   Skrahina, Alena ^h   Tagliani, Elisa ⁱ   Cirillo, Daniela M ⁱ   Davidow, Amy ^a   Denkinger, Claudia M ^e   Persing, David ^b   Kwiatkowski, Robert ^b   Jones, Martin ^b   Alland, David ^a   more..

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b CEPHEID   (United States)

^c Cepheid   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^f National Centre for Tuberculosis and Lung Disease   (Georgia)

^g P D HINDUJA NATIONAL HOSPITAL   (India)

^h Republican Scientific and Practical Centre for Pulmonology and Tuberculosis   (Belarus)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Diagnosis; Sensitive; Tuberculosis; Xpert MTB RIF Ultra

Indexed keywords

BACTERIAL DNA; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; BACTERIAL PROTEIN; DNA DIRECTED RNA POLYMERASE; RPOB PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; COLONY FORMING UNIT; CONTROLLED STUDY; FALSE POSITIVE RESULT; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPUTUM ANALYSIS; TUBERCULOSIS RAPID TEST; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MUTATION; POLYMERASE CHAIN REACTION; PROCEDURES; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; DNA-DIRECTED RNA POLYMERASES; HUMANS; LIMIT OF DETECTION; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE TESTING; POLYMERASE CHAIN REACTION; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 85029160482     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00812-17     Document Type: Article

References (24)

1. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NT, Jones-López EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D. 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of ondemand, near-patient technology. J Clin Microbiol 48:229-237. https://doi.org/10.1128/JCM.01463-09.
2. Steingart KR, Si HDJ, Pai M, Boehme CC, Dendukuri N. 2014. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1:CD009593. https://doi.org/10.1002/14651858.CD009593.pub3.
3. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. 2016. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J 48:516-525. https://doi.org/10.1183/13993003.00543-2016.
4. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O’Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005–1015. https://doi.org/10.1056/NEJMoa0907847.
5. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker LG, Wood R. 2011. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8:e1001067. https://doi.org/10.1371/journal.pmed.1001067.
6. Sohn H, Aero AD, Menzies D, Behr M, Schwartzman K, Alvarez GG, Dan A, McIntosh F, Pai M, Denkinger CM. 2014. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis 58:970-976. https://doi.org/10.1093/cid/ciu022.
7. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, TB-NEAT Team. 2014. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primarycare settings in Africa: a multicentre, randomised, controlled trial. Lancet 383:424-435. https://doi.org/10.1016/S0140-6736(13)62073-5.
8. Theron G, Peter J, Calligaro G, Meldau R, Hanrahan C, Khalfey H, Matinyenya B, Muchinga T, Smith L, Pandie S, Lenders L, Patel V, Mayosi BM, Dheda K. 2014. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Sci Rep 4:5658. https://doi.org/10.1038/srep05658.
9. Zeka AN, Tasbakan S, Cavusoglu C. 2011. Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. J Clin Microbiol 49:4138-4141. https://doi.org/10.1128/JCM.05434-11.
10. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. 2014. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J 44: 435-446. https://doi.org/10.1183/09031936.00007814.
11. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D. 2010. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 48:2495–2501. https://doi.org/10.1128/JCM.00128-10.
12. Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, Collman RG, Klausner JD, Modongo C. 2014. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol 52:2422–2429. https://doi.org/10.1128/JCM.02489-13.
13. Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S. 2014. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis. J Clin Microbiol 52:1846-1852. https://doi.org/10.1128/JCM.03005-13.
14. Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA. 2012. An evaluation of the Xpert MTB/RIF assay and detection of falsepositive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 74:207–209. https://doi.org/10.1016/j.diagmicrobio.2012.06.013.
15. Köser CU, Feuerriegel S, Summers DK, Archer JA, Niemann S. 2012. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 56:6080-6087. https://doi.org/10.1128/AAC.01641-12.
16. Chakravorty S, Kothari H, Aladegbami B, Cho EJ, Lee JS, Roh SS, Kim H, Kwak H, Lee EG, Hwang SH, Banada PP, Safi H, Via LE, Cho SN, Barry CE III, Alland D. 2012. Rapid, high-throughput detection of rifampin resistance and heteroresistance in Mycobacterium tuberculosis by use of sloppy molecular beacon melting temperature coding. J Clin Microbiol 50:2194-2202. https://doi.org/10.1128/JCM.00143-12.
17. Gagneux S, Small PM. 2007. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7:328-337. https://doi.org/10.1016/S1473-3099(07)70108-1.
18. Lok KH, Benjamin WH, Jr, Kimerling ME, Pruitt V, Lathan M, Razeq J, Hooper N, Cronin W, Dunlap NE. 2002. Molecular differentiation of Mycobacterium tuberculosis strains without IS6110 insertions. Emerg Infect Dis 8:1310-1313. https://doi.org/10.3201/eid0811.020291.
19. Ioannidis P, Papaventsis D, Karabela S, Nikolaou S, Panagi M, Raftopoulou E, Konstantinidou E, Marinou I, Kanavaki S. 2011. Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results. J Clin Microbiol 49:3068-3070. https://doi.org/10.1128/JCM.00718-11.
20. Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, Mendelson M. 2014. False-positive Xpert® MTB/RIF assays in previously treated patients: need for caution in interpreting results. Int J Tuberc Lung Dis 18:876-878. https://doi.org/10.5588/ijtld.13.0853.
21. Schumacher SG, Nabeta P, Boehme CC, Ellner J, Alland D, Dorman SE, Denkinge CM. 2017. A multicenter diagnostic accuracy study of the Xpert Ultra for tuberculosis diagnosis. Conf Retroviruses Oppor Infect, Seattle, WA, 13 to 16 February 2017. http://www.croiconference.org/sessions/multicenter-diagnostic-accuracy-study-xpert-ultra-tuberculosis -diagnosis.
22. Eisenach KD, Crawford JT, Bates JH. 1988. Repetitive DNA sequences as probes for Mycobacterium tuberculosis. J Clin Microbiol 26:2240-2245.
23. Thierry D, Cave MD, Eisenach KD, Crawford JT, Bates JH, Gicquel B, Guesdon JL. 1990. IS6110, an IS-like element of Mycobacterium tuberculosis complex. Nucleic Acids Res 18:188. https://doi.org/10.1093/nar/18.1.188.
24. van Soolingen D, Hermans PW, de Haas PE, van Embden JD. 1992. Insertion element IS1081-associated restriction fragment length polymorphisms in Mycobacterium tuberculosis complex species: a reliable tool for recognizing Mycobacterium bovis BCG. J Clin Microbiol 30: 1772–1777.